I don't think we can nail it down to one, because nobody does it perfectly.
Canada, as you know, is a wonderful hybrid. We can learn from everybody. I think that's where we want to go.
We can look at what France does in terms of providing it immediately. We can look at what Germany does: have a managed access scheme that brings in the drugs, and we'll renegotiate the price after a year. We can look at the U.K., which says it has a highly specialized approach for ultra-orphan drugs.
We can adopt all of those in our proposal for a managed access scheme in Canada. Bringing in those drugs and making them available to people under a monitoring system, with information that will allow us to decide who can continue and what the right pricing is over a period of time, we think picks up all the best of those.
Canada can step up, and I think other countries can say, “Why don't we do what what Canada does?”